Product Details
| Product Name:
ACY-1083 |
CAS No.:
1708113-43-2 |
| Purity:
99.19% |
Supply Ability:
10g |
| Release date:
2026/05/15 |
Product Introduction
Bioactivity
| Name | ACY-1083 |
| Description | ACY-1083 is a small molecule inhibitor, a highly selective HDAC6 inhibitor (IC50=3 nM), with 260-fold higher selectivity over other classes of HDAC isoforms. It is brain-penetrant and used for research on chemotherapy-induced peripheral neuropathy. |
| In vitro | Methods: Air-liquid interface cultures of bronchial epithelial cells derived from COPD patients were treated with 10 μM ACY-1083, and stimulated with TNF, TGF-β, cigarette smoke, or bacteria. Epithelial barrier function (TEER, FITC-dextran permeability), inflammatory factors (MSD, qPCR), morphology (AB/PAS staining), and ciliary function were detected.
Results: ACY-1083 significantly reduced stimulus-induced permeability increase, decreased release of inflammatory factors such as IL-6 and CCL2, protected epithelial morphology and ciliary function, and maintained mucus clearance.[1] |
| In vivo | Methods: In adult male SD rat models, ACY-1083 (3 mg/kg) was administered orally to detect its reversal effect on paclitaxel-induced mechanical allodynia; in C57BL/6J mice, ACY-1083 (5 mg/kg) was administered via intraperitoneal injection for pharmacokinetic analysis, detecting blood drug concentration, half-life, and biologically effective plasma exposure time.
Results: ACY-1083 reversed paclitaxel-induced mechanical allodynia. ACY-1083 exhibited a maximum blood concentration (Cmax) of 936 ng/mL, a half-life (T1/2) of 3.5 hours, and 8 hours of biologically effective plasma exposure time. [1]
Methods: In C57BL/6J mouse models, ACY-1083 (10 mg/kg) was administered via intraperitoneal injection to detect its alleviating effect on cisplatin-induced mechanical allodynia.
Results: ACY-1083 effectively alleviated cisplatin-induced mechanical allodynia. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (14.35 mM), Sonication is recommended.
DMSO : 237.5 mg/mL (681.79 mM), Sonication is recommended.
|
| Keywords | HDAC6 | ACY-1083 | ACY1083 | ACY 1083 |
| Inhibitors Related | Panobinostat | Theophylline monohydrate | Valproic acid sodium salt | Methoxyacetic acid | Sodium 4-phenylbutyrate | Acefylline | Manganese chloride (tetrahydrate) | Curcumin | Valproic Acid | Sodium butanoate | 4-Phenylbutyric acid | Theophylline |
| Related Compound Libraries | Reprogramming Compound Library | Histone Modification Compound Library | DNA Damage & Repair Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Chromatin Modification Compound Library | Hematonosis Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1818291-27-8
$3100.00
-
-
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$155.00
|
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-16 |
|
|
$155.00
|
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-15 |
|
|
$155.00
|
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-05-02 |
United States